The controlling shareholder of Enwei Pharmaceutical (301331.SZ) plans to increase its holdings by 36 million to 72 million yuan.

Enwei Pharmaceutical (301331.SZ) announced that the company's controlling shareholder, Chengdu Enwei Investment (Group) Co., Ltd. (referred to as "Enwei Group"), and Chengdu Jiewei Enterprise Management Co., Ltd. (referred to as "Chengdu Jiewei/Increasing Holdings Entity"), as the concerted action party, have confidence in the company's future sustainable and stable development and long-term investment value. In order to enhance investor confidence, Chengdu Jiewei plans to increase its holdings of the company's A shares through centralized competitive bidding within 6 months from the date of this announcement. The overall increase in holdings shall not be less than RMB 36 million and not more than RMB 72 million. In accordance with the notice issued by the People's Bank of China, the China Banking and Insurance Regulatory Commission, and the China Securities Regulatory Commission on matters related to establishing stock repurchase and increase financing, the company meets the basic conditions for major shareholders to increase their shareholding. The company recently received a notification letter from the controlling shareholder Chengdu Jiewei, and Shanghai Pudong Development Bank Co., Ltd. Chengdu Branch issued a "Loan Commitment Letter" to Chengdu Jiewei for the special loan for stock increase, with the following main contents: 1. Loan amount: Shanghai Pudong Development Bank Co., Ltd. Chengdu Branch will provide Chengdu Jiewei with a special loan not exceeding RMB 50 million under the premise of meeting relevant loan conditions. 2. Loan purpose: Chengdu Jiewei shall use the loan for the specific purpose of purchasing Enwei Pharmaceutical Limited's shares (301331) through centralized competitive bidding, with the loan funds being "special-use and closed-loop operation". 3. Loan term: 12 months.